Role of Anthracycline and Comprehensive Geriatric Assessment for Elderly Patients with Diffuse Large B-cell Lymphoma

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2017 Aug 18

PMID 28814386

Citations 23

Authors

Richard J Lin

Madhusmita Behera

Catherine S Diefenbach

Christopher R Flowers

Affiliations

Soon will be listed here.

Abstract

Survival outcome for elderly patients with newly diagnosed diffuse large B-cell lymphoma remains suboptimal in the rituximab era. In this systematic review, we summarize available evidence relevant to the inclusion of anthracycline in upfront chemoimmunotherapy for these elderly patients and highlight the need of prospective clinical trials. With limited prospective data, we find that pretreatment comprehensive geriatric assessment accurately predicts survival and treatment-related toxicities, suggesting its potential role in guiding overall treatment decision-making.

Citing Articles

Diffuse Large B-Cell Lymphoma in the Older and Frail Patient.

Ayers E, Smith S Cancers (Basel). 2025; 17(5).

PMID: 40075732 PMC: 11899176. DOI: 10.3390/cancers17050885.

Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin Lymphoma.

Upshaw J, Nelson J, Sweigart B, Rodday A, Kumar A, Konstam M JACC CardioOncol. 2024; 6(2):200-213.

PMID: 38774008 PMC: 11103040. DOI: 10.1016/j.jaccao.2024.02.003.

Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials.

Atallah-Yunes S, Khurana A, Maurer M Leuk Lymphoma. 2024; 65(4):430-439.

PMID: 38180317 PMC: 10932918. DOI: 10.1080/10428194.2023.2298705.

Hodgkin lymphoma treatment for older persons in the modern era.

Evens A, McKenna M, Tiger Y, Upshaw J Hematology Am Soc Hematol Educ Program. 2023; 2023(1):483-499.

PMID: 38066840 PMC: 10727079. DOI: 10.1182/hematology.2023000449.

Reduced-Intensity Anthracycline-Free Chemoimmunotherapy in Elderly Patients With Newly Diagnosed or Relapsed Diffuse Large B-Cell Lymphoma.

Yohannan B, Rios A J Hematol. 2023; 12(4):176-186.

PMID: 37692866 PMC: 10482608. DOI: 10.14740/jh1144.

References

. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329(14):987-94. DOI: 10.1056/NEJM199309303291402. View

Mohile S, Velarde C, Hurria A, Magnuson A, Lowenstein L, Pandya C . Geriatric Assessment-Guided Care Processes for Older Adults: A Delphi Consensus of Geriatric Oncology Experts. J Natl Compr Canc Netw. 2015; 13(9):1120-30. PMC: 4630807. DOI: 10.6004/jnccn.2015.0137. View

Hamlin P, Satram-Hoang S, Reyes C, Hoang K, Guduru S, Skettino S . Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis. Oncologist. 2014; 19(12):1249-57. PMC: 4257739. DOI: 10.1634/theoncologist.2014-0113. View

Scher K, Hurria A . Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol. 2012; 30(17):2036-8. DOI: 10.1200/JCO.2012.41.6727. View

Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C . Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005; 23(18):4117-26. DOI: 10.1200/JCO.2005.09.131. View

Rashidi A, Oak E, Carson K, Wagner-Johnston N, Kreisel F, Bartlett N . Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria. Leuk Lymphoma. 2015; 57(5):1191-3. DOI: 10.3109/10428194.2015.1096356. View

Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller A, Rube C . Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004; 104(3):634-41. DOI: 10.1182/blood-2003-06-2095. View

Byun J, Lee J, Kang B, Kim J, Kim S, Kim J . Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population. Clin Lymphoma Myeloma Leuk. 2016; 16(9):503-510.e3. DOI: 10.1016/j.clml.2016.06.003. View

Carson K, Riedell P, Lynch R, Nabhan C, Wildes T, Liu W . Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. J Geriatr Oncol. 2015; 6(3):211-8. PMC: 4605388. DOI: 10.1016/j.jgo.2015.01.003. View

10.

Mareschal S, Lanic H, Ruminy P, Bastard C, Tilly H, Jardin F . The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica. 2011; 96(12):1888-90. PMC: 3232277. DOI: 10.3324/haematol.2011.050617. View

11.

Chihara D, Westin J, Oki Y, Ahmed M, Do B, Fayad L . Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. 2016; 122(20):3145-3151. DOI: 10.1002/cncr.30173. View

12.

Tien Y, Link B, Brooks J, Wright K, Chrischilles E . Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile. Leuk Lymphoma. 2014; 56(1):65-71. PMC: 4383134. DOI: 10.3109/10428194.2014.903589. View

13.

Merli F, Luminari S, Rossi G, Mammi C, Marcheselli L, Ferrari A . Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. Leuk Lymphoma. 2013; 55(1):38-43. DOI: 10.3109/10428194.2013.788176. View

14.

Wieringa A, Boslooper K, Hoogendoorn M, Joosten P, Beerden T, Storm H . Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. Br J Haematol. 2014; 165(4):489-96. DOI: 10.1111/bjh.12765. View

15.

Morrison V, Hamlin P, Soubeyran P, Stauder R, Wadhwa P, Aapro M . Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper. J Geriatr Oncol. 2014; 6(2):141-52. DOI: 10.1016/j.jgo.2014.11.004. View

16.

Fields P, Linch D . Treatment of the elderly patient with diffuse large B cell lymphoma. Br J Haematol. 2012; 157(2):159-70. DOI: 10.1111/j.1365-2141.2011.09011.x. View

17.

Palumbo A, Bringhen S, Mateos M, Larocca A, Facon T, Kumar S . Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015; 125(13):2068-74. PMC: 4375104. DOI: 10.1182/blood-2014-12-615187. View

18.

Bastion Y, Blay J, Divine M, Brice P, Bordessoule D, Sebban C . Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol. 1997; 15(8):2945-53. DOI: 10.1200/JCO.1997.15.8.2945. View

19.

Repetto L, Biganzoli L, Koehne C, Luebbe A, Soubeyran P, Tjan-Heijnen V . EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer. 2003; 39(16):2264-72. DOI: 10.1016/s0959-8049(03)00662-2. View

20.

Fields P, Townsend W, Webb A, Counsell N, Pocock C, Smith P . De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. J Clin Oncol. 2013; 32(4):282-7. DOI: 10.1200/JCO.2013.49.7586. View